<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965781</url>
  </required_header>
  <id_info>
    <org_study_id>P2a</org_study_id>
    <nct_id>NCT02965781</nct_id>
  </id_info>
  <brief_title>Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis</brief_title>
  <acronym>P2a</acronym>
  <official_title>A Phase 2, Multi-site, Randomized, Double-blind, Vehicle-controlled Study of the Efficacy and Safety of Squaric Acid Dibutyl Ester (SADBE) in Subjects With Recurrent Herpes Labialis - Single Versus Two-dose Arm Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Squarex, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Squarex, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of SADBE in the prevention of recurrent herpes&#xD;
      labialis in adults. Two-thirds of the participants will receive a SADBE solution, while the&#xD;
      other third will receive only the vehicle as a placebo control. The solutions will be&#xD;
      administered topically to the patient's arms. The study will compare a single-arm application&#xD;
      versus a two-arm application versus two placebo doses on the arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">December 20, 2018</completion_date>
  <primary_completion_date type="Actual">December 20, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose</measure>
    <time_frame>43 - 121 days after the first dose</time_frame>
    <description>The number of days until a patient reports his or her first new herpes labialis episode from 43 - 121 days following the first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Outbreaks Beginning 43 Days After the First Dose up to 12 Months</measure>
    <time_frame>From day 43 after the first dose up to 12 months</time_frame>
    <description>The number of new herpes labialis episodes per subject during the 12-month follow up period following the first drug dose, beginning day 43 after the first dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Herpes Labialis</condition>
  <condition>Cold Sore</condition>
  <arm_group>
    <arm_group_label>One SADBE application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two SADBE applications</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo application (DMSO only-No SADBE)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SADBE</intervention_name>
    <description>Topical solution</description>
    <arm_group_label>One SADBE application</arm_group_label>
    <arm_group_label>Two SADBE applications</arm_group_label>
    <other_name>Squaric acid dibutyl ester</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical solution</description>
    <arm_group_label>One SADBE application</arm_group_label>
    <arm_group_label>Placebo application (DMSO only-No SADBE)</arm_group_label>
    <other_name>Vehicle-DMSO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18&#xD;
&#xD;
          -  Clinical diagnosis of herpes labialis, which may be made at the screening visit based&#xD;
             on the patient's self-reported history of symptoms. An active herpes labialis outbreak&#xD;
             at the time of entry into the clinical trial will neither be required nor will be an&#xD;
             exclusion criteria.&#xD;
&#xD;
          -  Self report having four or more episodes of herpes labialis in the past 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People that have had treatment with anti viral therapy within 2 weeks before&#xD;
             sensitization dose.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Current or recurrent non-herpetic infection or any underlying condition that may&#xD;
             predispose to infection or anyone who has been admitted to the hospital due to&#xD;
             bacteremia, pneumonia or any other serious infection.&#xD;
&#xD;
          -  Therapy with glucocorticoid or immunosuppressants at time of recruitment or within&#xD;
             past 4 weeks, except for inhaled corticosteroids for asthma or topical steroids in&#xD;
             sites other than face.&#xD;
&#xD;
          -  History of malignancy (except patients with surgically cured basal cell or squamous&#xD;
             cell skin cancers)&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  HIV-positive status determined by history at screening or known history of any other&#xD;
             immunosuppressive disease.&#xD;
&#xD;
          -  Severe co-morbidities (diabetes mellitus requiring insulin, CHF (EF&lt;50% at baseline&#xD;
             will be exclusionary) MI, CVA or TIA within 3 months of screening visit, unstable&#xD;
             angina pectoris, oxygen-dependent severe pulmonary disease&#xD;
&#xD;
          -  History of exposure to squaric acid or squaric acid dibutyl ester.&#xD;
&#xD;
          -  Known hypersensitivity to DMSO&#xD;
&#xD;
          -  Any condition judged by the investigator to cause this clinical trial to be&#xD;
             detrimental to the patient.&#xD;
&#xD;
          -  Subject is currently enrolled in another investigational device or drug trial(s), or&#xD;
             subject has received other investigational agent(s) within 28 days of baseline visit.&#xD;
&#xD;
          -  Previous or current participation in a clinical trial of SADBE to treat herpes&#xD;
             labialis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh McTavish, PhD, JD</last_name>
    <role>Study Director</role>
    <affiliation>Squarex, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas D Horn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Squarex, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Medicine Outpatient Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Partners, LLC</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research, Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advantage Clinical Trials</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <results_first_submitted>May 19, 2021</results_first_submitted>
  <results_first_submitted_qc>October 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squaric acid dibutyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02965781/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>One SADBE Application</title>
          <description>Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.&#xD;
SADBE: Topical solution&#xD;
Placebo: Topical solution</description>
        </group>
        <group group_id="P2">
          <title>Two SADBE Applications</title>
          <description>Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.&#xD;
SADBE: Topical solution</description>
        </group>
        <group group_id="P3">
          <title>Placebo Application (DMSO Only-No SADBE)</title>
          <description>Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.&#xD;
Placebo: Topical solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>One SADBE Application</title>
          <description>Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.&#xD;
SADBE: Topical solution&#xD;
Placebo: Topical solution</description>
        </group>
        <group group_id="B2">
          <title>Two SADBE Applications</title>
          <description>Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.&#xD;
SADBE: Topical solution</description>
        </group>
        <group group_id="B3">
          <title>Placebo Application (DMSO Only-No SADBE)</title>
          <description>Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.&#xD;
Placebo: Topical solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" lower_limit="19.8" upper_limit="82.6"/>
                    <measurement group_id="B2" value="44.2" lower_limit="23.8" upper_limit="80.4"/>
                    <measurement group_id="B3" value="50.1" lower_limit="21.1" upper_limit="82.6"/>
                    <measurement group_id="B4" value="47.1" lower_limit="19.8" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unasnswered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSV-1-neg / HSV-2 neg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSV-1-neg / HSV-2 pos</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSV-1-pos / HSV-2 neg</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSV-1-pos / HSV-2 pos</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median self-reported prior outbreaks over 12 months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>4 or 5 prior outbreaks</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 or more prior outbreaks</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose</title>
        <description>The number of days until a patient reports his or her first new herpes labialis episode from 43 - 121 days following the first dose</description>
        <time_frame>43 - 121 days after the first dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Application (DMSO Only-No SADBE)</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Two SADBE Applications</title>
            <description>2-dose</description>
          </group>
          <group group_id="O3">
            <title>One SADBE Application</title>
            <description>1-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose</title>
          <description>The number of days until a patient reports his or her first new herpes labialis episode from 43 - 121 days following the first dose</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="4" upper_limit="318"/>
                    <measurement group_id="O2" value="163" lower_limit="7" upper_limit="318"/>
                    <measurement group_id="O3" value="174" lower_limit="17" upper_limit="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Outbreaks Beginning 43 Days After the First Dose up to 12 Months</title>
        <description>The number of new herpes labialis episodes per subject during the 12-month follow up period following the first drug dose, beginning day 43 after the first dose</description>
        <time_frame>From day 43 after the first dose up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Application (DMSO Only-No SADBE)</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Two SADBE Applications</title>
            <description>2-dose</description>
          </group>
          <group group_id="O3">
            <title>One SADBE Application</title>
            <description>1-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Outbreaks Beginning 43 Days After the First Dose up to 12 Months</title>
          <description>The number of new herpes labialis episodes per subject during the 12-month follow up period following the first drug dose, beginning day 43 after the first dose</description>
          <units>outbreaks per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.610" spread="0.802"/>
                    <measurement group_id="O2" value="0.500" spread="0.849"/>
                    <measurement group_id="O3" value="0.231" spread="0.427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Year</time_frame>
      <desc>Subjects receiving One or Two doses of SADBE were combined for Adverse Event Reporting because they did not experience adverse events at different incidence rates.&#xD;
The terms mild, moderate, and severe were undefined except &quot;severe&quot; was defined as requiring topical corticosteroid treatment and none of these events correspond to a serious adverse event or to Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 terms for skin and subcutaneous tissue disorders.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Application (DMSO Only-No SADBE)</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>Two SADBE Applications</title>
          <description>2-dose</description>
        </group>
        <group group_id="E3">
          <title>One SADBE Application</title>
          <description>1-dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dead skin at application site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dermatitis at application site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Erythema, stain, or rash at application site</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Erythema distal from application site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Flushed burning sensation on face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Herpes lesion on genitals, anus, or spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Irritation, itching at application site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Irritation, itching distal from application site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pimple</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Purpura at application site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Papule on lip</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dermatitis from adhesive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Burning at application site.</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tingling, stinging at application site</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tingling distal from application site</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Boil at application site</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hugh McTavish</name_or_title>
      <organization>Squarex LLC</organization>
      <phone>6512078270</phone>
      <email>hmctavish@squarex-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

